Brillinta

Showing 6 posts of 6 posts found.

Efient fails to prove superiority to Plavix

August 29, 2012
Brillinta, Efient, Plavix, prasugrel, ticagrelor

Daiichi Sankyo and Lilly’s heart drug Efient has failed to come up to the mark in a late-stage trial which …

AZ’s antiplatelet recommended for European approval

September 27, 2010
Sales and Marketing Brilinta, Brilique, Brillinta, Possia

AstraZeneca’s oral antiplatelet treatment Brilique has received a positive opinion from a key European advisory committee. A marketing authorisation for …

AstraZeneca’s Brilinta delayed

September 16, 2010
Sales and Marketing Brillinta, Effient, Plavix, clopidogrel

AstraZeneca’s blood thinning drug Brilinta faces an extra three month delay to its review by the FDA. The US regulator …

FDA recommends Brilinta

July 30, 2010
Sales and Marketing 2010 financials, AstraZeneca, Brillinta, Q2

FDA advisors have voted in favour of AstraZeneca’s antiplatelet drug Brilinta, which is currently seeking a licence for the reduction …

Head-to-head boost for Brilinta over Plavix

September 4, 2009
Research and Development, Sales and Marketing AZ, Brillinta

 AstraZeneca has released details of its brand Brilinta’s performance in head-to-head trials with Plavix, the world’s second biggest-selling drug.Earlier this …

AstraZeneca buoyed as Brilinta tops Plavix in trial

May 13, 2009
Research and Development, Sales and Marketing AZ, Brillinta

AstraZeneca has been lifted by clinical results indicating its antiplatelet drug Brilinta outperformed Sanofi-Aventis/Bristol-Myers Squibb’s Plavix – currently the world’s …

The Gateway to Local Adoption Series

Latest content